Mednet Logo
CommunityHematology

Do you attempt treatment breaks from bispecific antibody therapy in patients with relapsed myeloma who achieve a sustained MRD-negative complete response?

Community PollStarted

When do you consider treatment breaks from bispecific antibody therapy in patients with relapsed myeloma?

35 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on

I have not seen any reported data on this, so no.

Here is the only information that I have adjacent to this question:

  1. I generally don't repeat bone marrow biopsies on patients receiving bispecific antibody therapy, so I have little experience with sustained MRD-negative CR's. I certainly have done ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of North Carolina Chapel Hill
Answered on

I don't attempt to stop therapy in people who achieve deep responses and are tolerating the drug, but this is mostly because there is currently a paucity of prospective trials, so the specific time at which stopping therapy is optimal has not been established. I do have a low threshold to space out ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · MSKCC
Answered on · Updated on

If the patient has had at least 12 months of therapy and has achieved MRD-negative complete response, I would give consideration to treatment breaks, especially if the patient has had significant issues with hypogammaglobulinemia, infections, or the desire to be off therapy. The patient does not nee...

Join for free or sign in to see the full answer